Ligand Pharmaceuticals has recently experienced a notable surge in its stock value, almost tripling from its 52-week low. This upward trend culminated in a significant jump during the last week of June, driven largely by a financing event: the pricing of $625 million in convertible notes due in 2031. These funds are specifically earmarked for the acquisition of XOMA. While this acquisition promises to expand Ligand's royalty portfolio and pipeline, the current high valuation suggests that the stock's future performance is heavily reliant on sustained market re-rating, posing a potential risk for investors.

The company's stock performance over the past year has been remarkable, climbing from $112 to $306. The immediate catalyst for its recent leap was the announcement of the convertible notes, structured with a conversion price of approximately $334, representing a 27.5% premium over the reference price of $262. This strategic financial maneuver is aimed at funding the acquisition of XOMA, which is anticipated to be a pivotal factor in Ligand's future growth narrative. This move highlights a deliberate shift towards bolstering its intellectual property and revenue streams.

The acquisition of XOMA is expected to significantly enhance Ligand's position by adding over 120 royalties to its existing portfolio. This expansion, coupled with the optionality provided by Palvella's pipeline, is projected to underpin an embedded annual growth rate exceeding 20% and contribute substantially to future cash flow. Such a diversified and robust royalty base is central to the bull case for Ligand, transforming it into what some might describe as a 'Biotech ARM'—a company that generates revenue from intellectual property without incurring the full costs and risks of drug development.

Despite the optimistic outlook driven by the XOMA acquisition and expected growth, the current valuation of Ligand Pharmaceuticals warrants a cautious approach. Trading at around $304 with a forward EPS of 27x, the stock's future upside largely depends on the market's continued willingness to assign a premium compounder multiple. A shift in market sentiment or any negative narrative could expose the stock to considerable downside risk, potentially a 51% reduction to align with peer multiples. This asymmetry means that while a fresh breakout on fundamental change offers significant upside, a stock that has already tripled on a financing event presents a less favorable risk-reward profile.

To mitigate the risk associated with the current high valuation, investors might consider a more conservative entry point. A pullback to the $215-$240 range would offer a greater valuation cushion. Alternatively, a clear 'beat-and-raise' scenario, possibly at the December 2026 Investor Day, demonstrating strong earnings momentum, could also justify an upgrade to a 'Buy' rating. Without these factors, the stock's recent performance appears more driven by financial engineering and speculative interest than by undervalued fundamental strengths.